MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.250
0.000
0.00%
After Hours: 1.230 -0.02 -1.60% 19:49 09/21 EDT
OPEN
1.270
PREV CLOSE
1.250
HIGH
1.280
LOW
1.225
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
3.111
52 WEEK LOW
1.150
MARKET CAP
165.96M
P/E (TTM)
-1.7834
1D
5D
1M
3M
1Y
5Y
ADMA Biologics Shares Spike On Volume, Co. Files U.S. Patent Application For 'IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS'
https://pdfaiw.uspto.gov/.aiw?PageNum=0&docid=20210277093
Benzinga · 09/09 14:24
IGC, NCMI and BBIG among pre market gainers
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
Seekingalpha · 09/08 12:21
ADMA Biologics' Aseptic Fill-Finish Machine Scores FDA Approval
Benzinga · 09/08 12:08
BRIEF-ADMA Biologics Receives FDA Approval For VanRx Aseptic Fill-Finish Machine And Related Operations
reuters.com · 09/08 11:04
ADMA Biologics Secures FDA Approval for VanRx Aseptic Fill-Finish Machine - Shares Climb Pre-Bell
MT Newswires · 09/08 08:02
Cassava Sciences, NRx Pharmaceuticals, Innate Pharma among major healthcare premarket losers' pack
Jaguar Health (NASDAQ:JAGX) -21% slumps 10% on 1-for-3 reverse stock split announcement. Forward Pharma (NASDAQ:FWP) -17% after Technical Board of Appeal of the European Patent Office has dismissed Forward’s appeal of the previous
Seekingalpha · 09/07 12:22
BRIEF-Adma Biologics Inc Enters Into Distribution Agreement For Potential Offering Of Up To $50 Million
reuters.com · 09/03 21:16
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for ...
Benzinga · 08/20 12:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of ADMA Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMA stock price target is 6.60 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 131
Institutional Holdings: 50.76M
% Owned: 38.23%
Shares Outstanding: 132.77M
TypeInstitutionsShares
Increased
20
3.18M
New
17
1.84M
Decreased
35
8.22M
Sold Out
31
2.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
No Data
  • All
  • Financials
  • Insiders
More
About ADMA
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.